Literature DB >> 27765859

Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.

Andreas Hahn1, Martin Schain2, Maria Erlandsson3, Petter Sjölin3, Gregory M James4, Olof T Strandberg2, Douglas Hägerström5, Rupert Lanzenberger4, Jonas Jögi6, Tomas G Olsson3, Ruben Smith7, Oskar Hansson8,9.   

Abstract

Aggregation of hyperphosphorylated tau is a major hallmark of many neurodegenerative diseases, including Alzheimer disease (AD). In vivo imaging with PET may offer important insights into pathophysiologic mechanisms, diagnosis, and disease progression. We describe different strategies for quantification of 18F-AV-1451 (T807) tau binding, including models with blood sampling and noninvasive alternatives.
Methods: Fifteen subjects (4 controls, 6 AD, 3 progressive supranuclear palsy, 2 cortico basal syndrome) underwent 180-min PET with 18F-AV-1451 and arterial blood sampling. Modeling with arterial input functions included 1-, 2-, and 3-tissue-compartment models and the Logan plot. Using the cerebellum as reference region, we applied the simplified reference tissue model 2 and Logan reference plot. Finally, simplified outcome measures were calculated as ratio, with reference to cerebellar concentrations (SUV ratio [SUVR]) and SUVs.
Results: Tissue compartment models were not able to describe the kinetics of 18F-AV-1451, with poor fits in 33%-53% of cortical regions and 80% in subcortical areas. In contrast, the Logan plot showed excellent fits and parameter variance (total volume of distribution SE < 5%). Compared with the 180-min arterial-based Logan model, strong agreement was obtained for the Logan reference plot also for a reduced scan time of 100 min (R2 = 0.91) and SUVR 100-120 min (R2 = 0.94), with 80-100 min already representing a reasonable compromise between duration and accuracy (R2 = 0.93). Time-activity curves and kinetic parameters were equal for cortical regions and the cerebellum in control subjects but different in the putamen. Cerebellar total volumes of distribution were higher in controls than patients. For these methods, increased cortical binding was observed for AD patients and to some extent for cortico basal syndrome, but not progressive supranuclear palsy.
Conclusion: The Logan plot provided the best estimate of tau binding using arterial input functions. Assuming that the cerebellum is a valid reference region, simplified methods seem to provide robust alternatives for quantification, such as the Logan reference plot with 100-min scan time. Furthermore, SUVRs between target and cerebellar activities obtained from an 80- to 100-min static scan offer promising potential for clinical routine application.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  kinetic modeling; positron emission tomography; quantification; tau imaging

Mesh:

Substances:

Year:  2016        PMID: 27765859     DOI: 10.2967/jnumed.116.174508

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  25 in total

1.  Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Authors:  Kerstin Heurling; Ruben Smith; Olof T Strandberg; Martin Schain; Tomas Ohlsson; Oskar Hansson; Michael Schöll
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-03       Impact factor: 6.200

2.  Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain.

Authors:  Hiroto Kuwabara; Robert A Comley; Edilio Borroni; Michael Honer; Kelly Kitmiller; Joshua Roberts; Lorena Gapasin; Anil Mathur; Gregory Klein; Dean F Wong
Journal:  J Nucl Med       Date:  2018-08-10       Impact factor: 10.057

3.  PET imaging of tau protein targets: a methodology perspective.

Authors:  Cristina Lois; Ivan Gonzalez; Keith A Johnson; Julie C Price
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

4.  Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease.

Authors:  Yun Zhou; Shaney Flores; Syahir Mansor; Russ C Hornbeck; Zhude Tu; Joel S Perlmutter; Beau Ances; John C Morris; Robert J Gropler; Tammie L S Benzinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-18       Impact factor: 9.236

5.  18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Authors:  Daniel R Schonhaut; Corey T McMillan; Salvatore Spina; Bradford C Dickerson; Andrew Siderowf; Michael D Devous; Richard Tsai; Joseph Winer; David S Russell; Irene Litvan; Erik D Roberson; William W Seeley; Lea T Grinberg; Joel H Kramer; Bruce L Miller; Peter Pressman; Ilya Nasrallah; Suzanne L Baker; Stephen N Gomperts; Keith A Johnson; Murray Grossman; William J Jagust; Adam L Boxer; Gil D Rabinovici
Journal:  Ann Neurol       Date:  2017-10       Impact factor: 10.422

6.  In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Authors:  Ruben Smith; Michael Schöll; Håkan Widner; Danielle van Westen; Per Svenningsson; Douglas Hägerström; Tomas Ohlsson; Jonas Jögi; Christer Nilsson; Oskar Hansson
Journal:  Neurology       Date:  2017-07-28       Impact factor: 9.910

7.  18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Authors:  Niklas Mattsson; Michael Schöll; Olof Strandberg; Ruben Smith; Sebastian Palmqvist; Philip S Insel; Douglas Hägerström; Tomas Ohlsson; Henrik Zetterberg; Jonas Jögi; Kaj Blennow; Oskar Hansson
Journal:  EMBO Mol Med       Date:  2017-09       Impact factor: 12.137

Review 8.  Tau PET imaging: present and future directions.

Authors:  Laure Saint-Aubert; Laetitia Lemoine; Konstantinos Chiotis; Antoine Leuzy; Elena Rodriguez-Vieitez; Agneta Nordberg
Journal:  Mol Neurodegener       Date:  2017-02-20       Impact factor: 14.195

9.  Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.

Authors:  Niklas Mattsson; Ruben Smith; Olof Strandberg; Sebastian Palmqvist; Michael Schöll; Philip S Insel; Douglas Hägerström; Tomas Ohlsson; Henrik Zetterberg; Kaj Blennow; Jonas Jögi; Oskar Hansson
Journal:  Neurology       Date:  2018-01-10       Impact factor: 9.910

10.  18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

Authors:  Ruben Smith; Michael Schöll; Elisabet Londos; Tomas Ohlsson; Oskar Hansson
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.